Hisamitsu Pharmaceutical Co., Inc.
Consolidated Financial Summary for the Fiscal Year Ending February 2026 (Japanese GAAP)
For the fiscal year ending February 2026, consolidated net sales were JPY 163.024 billion (an increase of 4.5% YoY), operating income was JPY 17.917 billion (a decrease of 5.2% YoY), and net income attributable to owners of parent was JPY 19.16 billion (a decrease of 11.9% YoY).
Key Figures
- Net Sales: 163,024 million JPY (4.5% increase YoY)
- Operating Income: 17,917 million JPY (5.2% decrease YoY)
- Net Income Attributable to Owners of Parent: 19,160 million JPY (11.9% decrease YoY)
AI要約
Overview of Performance
For the fiscal year ending February 2026, consolidated net sales amounted to JPY 163,024 million (up 4.5% YoY), operating income was JPY 17,917 million (down 5.2% YoY), ordinary income was JPY 23,952 million (down 0.2% YoY), and net income attributable to owners of parent was JPY 19,160 million (down 11.9% YoY). In the pharmaceutical business, promotional activities leveraging digital marketing focused on transdermal patches were advanced domestically and internationally. In the overseas over-the-counter pharmaceutical market, the Salonpas brand maintained its position as the No. 1 product by sales share and continued to be recognized as the world's No.1 brand.
Financial Position and Dividend Status
At the end of the fiscal year ending February 2026, total assets were JPY 367,162 million, net assets were JPY 294,694 million with an equity ratio of 79.4%. The number of shares outstanding was 75,164,895, with treasury shares reduced to 4,763,348. A year-end dividend of 60 yen (annual dividend of 60 yen) was paid, resulting in a dividend payout ratio of 22.3% and a return on equity-based dividend of 1.5%. Note that earnings forecast for the fiscal year ending February 2027 is not disclosed due to a planned delisting following a tender offer.
